Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dizal Pharma
Pharma
Dizal's Zegfrovy adds more pressure to J&J's Rybrevant
The success of the Wu-Kong28 study shows Zegfrovy's potential as the first oral, chemo-free regimen in first-line EGFR exon 20-mutated NSCLC.
Angus Liu
Mar 23, 2026 10:25am
Lilly-Innovent, Dizal, bispecific ADC—Fierce Pharma Asia
Jul 10, 2025 5:20pm
FDA signs off on AZ spinout Dizal's lung cancer drug Zegfrovy
Jul 7, 2025 11:28am
Daiichi-Merck, Wegovy, Takeda CEO—Fierce Pharma Asia
Jun 28, 2024 8:40am
Despite J&J's full nod, FDA endorses Dizal's accelerated plan
Jun 26, 2024 11:08am
BMS, China reimbursement update, CAR-T hold—Fierce Pharma Asia
Dec 15, 2023 5:15am
